Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
BMC Psychiatry ; 24(1): 23, 2024 01 04.
Article in English | MEDLINE | ID: mdl-38177999

ABSTRACT

BACKGROUND: Many rare genetic neurodevelopmental disorders (RGNDs) are characterized by intellectual disability (ID), severe cognitive and behavioral impairments, potentially diagnosed as a comorbid autism spectrum disorder or attention-deficit hyperactivity disorder. Quality of life is often impaired due to irritability, aggression and self-injurious behavior, generally refractory to standard therapies. There are indications from previous (case) studies and patient reporting that cannabidiol (CBD) may be an effective treatment for severe behavioral manifestations in RGNDs. However, clear evidence is lacking and interventional research is challenging due to the rarity as well as the heterogeneity within and between disease groups and interindividual differences in treatment response. Our objective is to examine the effectiveness of CBD on severe behavioral manifestations in three RGNDs, including Tuberous Sclerosis Complex (TSC), mucopolysaccharidosis type III (MPS III), and Fragile X syndrome (FXS), using an innovative trial design. METHODS: We aim to conduct placebo-controlled, double-blind, block-randomized, multiple crossover N-of-1 studies with oral CBD (twice daily) in 30 patients (aged ≥ 6 years) with confirmed TSC, MPS III or FXS and severe behavioral manifestations. The treatment is oral CBD up to a maximum of 25 mg/kg/day, twice daily. The primary outcome measure is the subscale irritability of the Aberrant Behavior Checklist. Secondary outcome measures include (personalized) patient-reported outcome measures with regard to behavioral and psychiatric outcomes, disease-specific outcome measures, parental stress, seizure frequency, and adverse effects of CBD. Questionnaires will be completed and study medication will be taken at the participants' natural setting. Individual treatment effects will be determined based on summary statistics. A mixed model analysis will be applied for analyzing the effectiveness of the intervention per disorder and across disorders combining data from the individual N-of-1 trials. DISCUSSION: These N-of-1 trials address an unmet medical need and will provide information on the effectiveness of CBD for severe behavioral manifestations in RGNDs, potentially generating generalizable knowledge at an individual-, disorder- and RGND population level. TRIAL REGISTRATION: EudraCT: 2021-003250-23, registered 25 August 2022, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003250-23/NL .


Subject(s)
Autism Spectrum Disorder , Cannabidiol , Fragile X Syndrome , Mucopolysaccharidoses , Tuberous Sclerosis , Humans , Cannabidiol/therapeutic use , Fragile X Syndrome/complications , Fragile X Syndrome/drug therapy , Tuberous Sclerosis/complications , Tuberous Sclerosis/drug therapy , Autism Spectrum Disorder/drug therapy , Quality of Life , Treatment Outcome , Mucopolysaccharidoses/chemically induced , Mucopolysaccharidoses/drug therapy , Randomized Controlled Trials as Topic
2.
J Intellect Disabil Res ; 68(3): 248-263, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38009976

ABSTRACT

BACKGROUND: Angelman syndrome (AS) is a rare neurodevelopmental disorder characterised by severe intellectual disability, movement disorder, epilepsy, sleeping problems, and behavioural issues. Little is known on child health-related quality of life (HRQoL) in AS. AS family studies have reported elevated parenting stress and a high impact of the child's syndrome on the parent. It is unclear which factors influence child HRQoL and parenting stress/impact in AS. METHODS: We collected data prospectively through standardised clinical assessments of children with AS at the ENCORE Expertise centre for Angelman Syndrome at the Erasmus MC Sophia Children's Hospital. A linear regression analysis was conducted for the following outcome variables: (1) child HRQoL (Infant and Toddler Quality of Life Questionnaire); (2) the impact of the child's syndrome on the parent (Infant and Toddler Quality of Life Questionnaire); and (3) parenting stress (Parenting Stress Index). Predictor variables were child genotype, epilepsy, sleeping problems (Sleep Disturbance Scale for Children), cognitive developmental level (Bayley Cognition Scale), autistic features (Autism Diagnostic Observation Schedule) and emotional/behavioural problems (Child Behaviour Checklist). Covariates were sex, age and socio-economic status. RESULTS: The study sample consisted of 73 children with AS, mean age = 9.1 years, range = 2-18 years. Emotional/behavioural problems were the strongest significant predictor of lowered child HRQoL. Internalising problems were driving this effect. In addition, having the deletion genotype and higher age was related to lower child HRQoL. Sleeping problems were related to a higher impact of the child's syndrome on the parent. Finally, emotional/behavioural problems were associated with higher parenting stress. Cognitive developmental level, autistic features and epilepsy were not a significant predictor of child HRQoL and parenting stress/impact. CONCLUSIONS: These results suggest that interventions aimed at increasing child HRQoL and decreasing parenting stress/impact in AS should focus on child emotional/behavioural problems and sleeping problems, using a family-centred approach.


Subject(s)
Angelman Syndrome , Epilepsy , Sleep Wake Disorders , Infant , Humans , Child, Preschool , Child , Adolescent , Parenting , Quality of Life , Angelman Syndrome/complications , Sleep Wake Disorders/epidemiology
3.
Eur J Paediatr Neurol ; 21(4): 654-660, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28461111

ABSTRACT

OBJECTIVE: To define age-specific reference values for cerebrospinal fluid (CSF) total protein levels for children and validate these values in children with Guillain-Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS). METHODS: Reference values for CSF total protein levels were determined in an extensive cohort of diagnostic samples from children (<18 year) evaluated at Erasmus Medical Center/Sophia Children's Hospital. These reference values were confirmed in children diagnosed with disorders unrelated to raised CSF total protein level and validated in children with GBS, ADEM and MS. RESULTS: The test results of 6145 diagnostic CSF samples from 3623 children were used to define reference values. The reference values based on the upper limit of the 95% CI (i.e. upper limit of normal) were for 6 months-2 years 0.25 g/L, 2-6 years 0.25 g/L, 6-12 years 0.28 g/L, 12-18 years 0.34 g/L. These reference values were confirmed in a subgroup of 378 children diagnosed with disorders that are not typically associated with increased CSF total protein. In addition, the CSF total protein levels in these children in the first 6 months after birth were highly variable (median 0.47 g/L, IQR 0.26-0.65). According to these new reference values, CSF total protein level was elevated in 85% of children with GBS, 66% with ADEM and 23% with MS. CONCLUSION: More accurate age-specific reference values for CSF total protein levels in children were determined. These new reference values are more sensitive than currently used values for diagnosing GBS and ADEM in children.


Subject(s)
Cerebrospinal Fluid/chemistry , Child , Child, Preschool , Cohort Studies , Encephalomyelitis, Acute Disseminated/cerebrospinal fluid , Female , Guillain-Barre Syndrome/cerebrospinal fluid , Humans , Male , Reference Values
4.
J Neurol ; 264(1): 161-167, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27878438

ABSTRACT

Cognitive development in patients with tuberous sclerosis complex is highly variable. Predictors in the infant years would be valuable to counsel parents and to support development. The aim of this study was to confirm factors that have been reported to be independently correlated with cognitive development. 102 patients included in this study were treated at the ENCORE-TSC expertise center of the Erasmus Medical Center-Sophia Children's Hospital. Data from the first 24 months of life were used, including details on epilepsy, motor development and mutation status. Outcome was defined as cognitive development (intellectual equivalent, IE) as measured using tests appropriate to the patients age and cognitive abilities (median age at testing 8.2 years, IQR 4.7-12.0). Univariable and multivariable regression analyses were used. In a univariable analysis, predictors of lower IE were: the presence of infantile spasms (ß = -18.3, p = 0.000), a larger number of antiepileptic drugs used (ß = -6.3, p = 0.000), vigabatrin not used as first drug (ß = -14.6, p = 0.020), corticosteroid treatment (ß = -33.2, p = 0.005), and a later age at which the child could walk independently (ß = -2.1, p = 0.000). An older age at seizure onset predicted higher IE (ß = 1.7, p = 0.000). In a multivariable analysis, only age at seizure onset was significantly correlated to IE (ß = 1.2, p = 0.005), contributing to 28% of the variation in IE. In our cohort, age at seizure onset was the only variable that independently predicted IE. Factors predicting cognitive development could aid parents and physicians in finding the appropriate support and schooling for these patients.


Subject(s)
Cognition , Intelligence , Tuberous Sclerosis/diagnosis , Tuberous Sclerosis/psychology , Age of Onset , Child , Child Development , Child, Preschool , Epilepsy/diagnosis , Epilepsy/epidemiology , Epilepsy/psychology , Epilepsy/therapy , Female , Follow-Up Studies , Humans , Intellectual Disability/diagnosis , Intellectual Disability/epidemiology , Intellectual Disability/genetics , Intelligence Tests , Male , Multivariate Analysis , Prognosis , Psychology, Child , Regression Analysis , Retrospective Studies , Tuberous Sclerosis/epidemiology , Tuberous Sclerosis/therapy
5.
Neurology ; 76(9): 807-10, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-21357832

ABSTRACT

OBJECTIVE: To determine whether recognition of Guillain-Barré syndrome (GBS) is delayed in preschool children, what causes this delay, and if the clinical presentation differs from older children. METHODS: In a retrospective cohort study, standardized data from all children with GBS seen at the Erasmus MC Sophia Children's University Hospital in Rotterdam from 1987 to 2009 were collected regarding clinical presentation, patient's delay, initial diagnosis, and doctor's delay to the diagnosis. We compared preschool children (<6 years old) with older children (6-18 years old). RESULTS: GBS was diagnosed in 23 preschool children and in 32 older children. Fifteen (68%) of the preschool children were initially misdiagnosed compared to 6 (21%) of the older children (p = 0.001). Median patient delay to consult a pediatrician in both age groups was the same (5.0 days). The median doctor's delay to diagnose possible GBS in preschool children was significantly longer than in older children (3 days vs 0 days). In one-quarter of preschool children, this doctor's delay was more than 1 week, up to 22 days. In preschool children, refusal to walk and pain in the legs were the most frequent presenting symptoms (65%), while older children presented with more classic symptoms of weakness and paresthesias. The preschool children were initially misdiagnosed with myopathy, tonsillitis, meningitis, rheumatoid disorders, coxitis, or discitis. CONCLUSION: The diagnosis of GBS in preschool children is delayed compared to older children. This delay is partly explained by the nonspecific clinical presentation, challenging neurologic examination, and alternative diagnoses in preschool children.


Subject(s)
Diagnostic Errors , Guillain-Barre Syndrome/diagnosis , Adolescent , Age Factors , Child , Child, Preschool , Cohort Studies , Fatal Outcome , Female , Guillain-Barre Syndrome/blood , Humans , Infant , Male , Retrospective Studies , Time Factors
6.
Eur J Med Genet ; 54(3): 299-300, 2011.
Article in English | MEDLINE | ID: mdl-21194575

ABSTRACT

Recently in this journal, Masurel-Paulet et al. reported the association between pulmonary disease and a mutation in X-linked FLNA in a male patient. We confirm this association in a female patient, showing that this complication is not sex-specific. Our patient has a FLNA missense mutation (c.220G > A) and presented with cerebral periventricular nodular heterotopia, cardiovascular abnormalities, and pulmonary disease consisting of lobar emphysema of the right middle pulmonary lobe with severe malacia of the right sided bronchus intermedius. Surgical resection of the right middle lobe was necessary and she had long-term oxygen dependency. Symptoms improved with age.


Subject(s)
Abnormalities, Multiple/genetics , Contractile Proteins/genetics , Lung Diseases/pathology , Microfilament Proteins/genetics , Mutation, Missense , Abnormalities, Multiple/pathology , Cardiovascular Abnormalities/pathology , Child, Preschool , Female , Filamins , Humans , Infant , Periventricular Nodular Heterotopia/pathology
7.
Mol Syndromol ; 1(3): 113-120, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21031080

ABSTRACT

Partial monosomy 21 has been reported, but the phenotypes described are variable with location and size of the deletion. We present 2 patients with a partially overlapping microdeletion of 21q22 and a striking phenotypic resemblance. They both presented with severe psychomotor delay, behavioral problems, no speech, microcephaly, feeding problems with frequent regurgitation, idiopathic thrombocytopenia, obesity, deep set eyes, down turned corners of the mouth, dysplastic ears, and small chin. Brain MRI showed cerebral atrophy mostly evident in frontal and temporal lobes, widened ventricles and thin corpus callosum in both cases, and in one patient evidence of a migration disorder. The first patient also presented with epilepsy and a ventricular septum defect. The second patient had a unilateral Peters anomaly. Microarray analysis showed a partially overlapping microdeletion spanning about 2.5 Mb in the 21q22.1-q22.2 region including the DYRK1A gene and excluding RUNX1. These patients present with a recognizable phenotype specific for this 21q22.1-q22.2 locus. We searched the literature for patients with overlapping deletions including the DYRK1A gene, in order to define other genes responsible for this presentation.

8.
Seizure ; 19(7): 450-2, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20637656

ABSTRACT

We report a case of a girl who presented with typical absence seizures at age of 4.5 years. EEG showed absence seizures of sudden onset with 3 Hz spike-and-waves that also correlated with the clinical absences. The seizure semiology included subtle deviation of the eyes which prompted MRI investigation of the brain. This showed a periventricular nodular heterotopia in the mid to anterior horn of the right lateral ventricle. Although possibly coincidental, periventricular heterotopia are considered to be epileptogenic and this association has been reported once before. Migration disorders, such as in the periventricular heterotopia of our patient, may influence the formation and excitability of the striato-thalamo-cortical network involved in the generation of 3 Hz spike-waves.


Subject(s)
Epilepsy, Absence/etiology , Epilepsy, Absence/pathology , Periventricular Nodular Heterotopia/complications , Periventricular Nodular Heterotopia/pathology , Anticonvulsants/therapeutic use , Child, Preschool , Drug Therapy, Combination , Electroencephalography , Epilepsy, Absence/drug therapy , Female , Humans , Lamotrigine , Magnetic Resonance Imaging , Triazines/administration & dosage , Valproic Acid/administration & dosage
9.
Neurogenetics ; 10(4): 333-6, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19384555

ABSTRACT

We report a child with a severe choreadystonic movement disorder, bilateral periventricular nodular heterotopia (BPNH), and secondary microcephaly based on compound heterozygosity for two new ARFGEF2 mutations (c.2031_2038dup and c.3798_3802del), changing the limited knowledge about the phenotype. The brain MRI shows bilateral hyperintensity of the putamen, BPNH, and generalized atrophy. Loss of ARFGEF2 function affects vesicle trafficking, proliferation/apoptosis, and neurotransmitter receptor function. This can explain BPNH and microcephaly. We hypothesize that the movement disorder and the preferential damage to the basal ganglia, specifically to the putamen, may be caused by an increased sensitivity to degeneration, a dynamic dysfunction due to neurotransmitter receptor mislocalization or a combination of both.


Subject(s)
Cell Movement/physiology , Guanine Nucleotide Exchange Factors/genetics , Movement Disorders/genetics , Mutation , Neurons/physiology , Periventricular Nodular Heterotopia/genetics , Abnormalities, Multiple/genetics , Base Sequence , Brain/cytology , Brain/pathology , Child , DNA Mutational Analysis , Female , Humans , Male , Microcephaly/genetics , Microcephaly/pathology , Molecular Sequence Data , Movement Disorders/pathology , Movement Disorders/physiopathology , Periventricular Nodular Heterotopia/pathology , Periventricular Nodular Heterotopia/physiopathology , Phenotype
10.
J Neurol Neurosurg Psychiatry ; 80(4): 426-8, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19289478

ABSTRACT

Filamin A is an important gene involved in the development of the brain, heart, connective tissue and blood vessels. A case is presented illustrating the challenge in recognising patients with filamin A mutations. The patient, a 71-year-old woman, was known to have heart valve disease and bilateral periventricular nodular heterotopia when she died of a subarachnoid haemorrhage. Autopsy showed typical cerebral bilateral periventricular heterotopia and vascular abnormalities. Postmortally, the diagnosis of a filamin A mutation was confirmed. Recognition during life may prevent cardiovascular problems and provide possibilities for genetic counselling.


Subject(s)
Contractile Proteins/genetics , Heart Defects, Congenital/etiology , Heart Defects, Congenital/genetics , Intracranial Aneurysm/etiology , Intracranial Aneurysm/genetics , Microfilament Proteins/genetics , Mutation/genetics , Mutation/physiology , Periventricular Nodular Heterotopia/etiology , Periventricular Nodular Heterotopia/genetics , Aged , Brain/pathology , Cerebral Angiography , DNA/genetics , Exons/genetics , Fatal Outcome , Female , Filamins , Heart Defects, Congenital/pathology , Humans , Intracranial Aneurysm/pathology , Magnetic Resonance Angiography , Periventricular Nodular Heterotopia/pathology , Tomography, X-Ray Computed
11.
Neurogenetics ; 7(4): 259-63, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16972080

ABSTRACT

Two families are presented with a child suffering from microcephaly with a simplified gyral pattern of the brain (SGP) and early onset insulin dependent diabetes mellitus (IDDM). The first patient was diagnosed postmortally with Wolcott-Rallison syndrome, after her younger brother developed IDDM, and a homozygous mutation in the eukaryotic translation initiation factor 2-alpha kinase 3 was found. The younger brother did not undergo magnetic resonance imaging (MRI). The patient from the second family has no EIF2AK3 mutation. SGP is considered to arise from decreased neuronal proliferation or increased apoptosis at an early stage of embryonal development, but insight into the pathways involved is minimal. EIF2AK3 is involved in translation initiation. It has been proposed that loss of function mutations reduce the ability of the cell to respond to endoplasmic reticulum stress, resulting in apoptosis of pancreatic Langerhans cells. Our findings suggest that in some cases, early onset IDDM and SGP can arise from common mechanisms leading to increased apoptosis.


Subject(s)
Cerebral Cortex/abnormalities , Diabetes Mellitus, Type 1/complications , Microcephaly/complications , Microcephaly/pathology , Age of Onset , Cerebral Cortex/pathology , Female , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Male , Osteochondrodysplasias/diagnostic imaging , Osteoporosis/diagnostic imaging , Radiography
12.
Mol Genet Metab ; 87(2): 102-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16275149

ABSTRACT

Malonyl-CoA decarboxylase (MCD) deficiency is an extremely rare inborn error of metabolism that presents with metabolic acidosis, hypoglycemia, and/or cardiomyopathy. Patients also show neurological signs and symptoms that have been infrequently reported. We describe a girl with MCD deficiency, whose brain MRI shows white matter abnormalities and additionally diffuse pachygyria and periventricular heterotopia, consistent with a malformation of cortical development. MLYCD-gene sequence analysis shows normal genomic sequence but no messenger product, suggesting an abnormality of transcription regulation. Our patient has strikingly low appetite, which is interesting in the light of the proposed role of malonyl-CoA in the regulation of feeding control, but this remains to be confirmed in other patients. Considering the incomplete understanding of the role of metabolic pathways in brain development, patients with MCD deficiency should be evaluated with brain MRI and unexplained malformations of cortical development should be reason for metabolic screening.


Subject(s)
Brain Diseases, Metabolic/genetics , Brain/abnormalities , Carboxy-Lyases/deficiency , Agenesis of Corpus Callosum , Brain Diseases, Metabolic/enzymology , Brain Stem/abnormalities , Carboxy-Lyases/genetics , Cells, Cultured , Cerebellum/abnormalities , Cerebral Cortex/abnormalities , Child, Preschool , DNA Mutational Analysis , Eating/genetics , Female , Fibroblasts/enzymology , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Middle Aged , Skin/cytology , Skin/enzymology
13.
Neurology ; 63(3): 535-7, 2004 Aug 10.
Article in English | MEDLINE | ID: mdl-15304589

ABSTRACT

To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.


Subject(s)
Artifacts , Brain Edema/etiology , Brain Neoplasms/radiotherapy , Cranial Irradiation , Dacarbazine/analogs & derivatives , Glioma/radiotherapy , Magnetic Resonance Imaging , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Astrocytoma/drug therapy , Astrocytoma/pathology , Astrocytoma/radiotherapy , Astrocytoma/surgery , Brain Edema/drug therapy , Brain Edema/pathology , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology , Brain Neoplasms/surgery , Chemotherapy, Adjuvant , Clinical Trials, Phase III as Topic/standards , Cohort Studies , Combined Modality Therapy , Contrast Media , Dacarbazine/administration & dosage , Dexamethasone/therapeutic use , Diagnosis, Differential , Disease Progression , Female , Follow-Up Studies , Gadolinium , Glioma/drug therapy , Glioma/pathology , Humans , Lomustine/administration & dosage , Male , Middle Aged , Patient Selection , Procarbazine/administration & dosage , Temozolomide , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...